| |
 |
HEPALIFE
TECHNOLOGIES, INC. (OTCBB: HPLF) |
 |
Dear Reader,
Every once in a while, we at StockUpTicks come across
a company that catches our eye because of its possibilities in
becoming a major player in its industry. That's what happened
with HepaLife Technologies, Inc. (OTCBB: HPLF). The company
caught our eye because it is developing an artificial liver device
for the 25 million Americans (1 in every 11) that suffer from
liver disease.
We're going to do some more digging and research on this very
exciting company, but we thought you might like to take a brief
look at it while we are preparing our complete profile.
The company recently initiated an ongoing investor relations
program in order to enhance it's visibility in the investment
community and we think that is a very positive step. Once HepaLife
increases its public profile, we think there will be a great deal
of interest from Wall Street.
Through a Cooperative Research and Development Agreement (CRADA)
with the USDA’s Agricultural Research Service, the primary tool
linking government and industry researchers, HepaLife is
currently collaborating towards optimizing the hepatic functions
of a patented cell line, whose hepatic characteristics have been
demonstrated to
have potential application in the production of an artificial
liver device for use by human patients with liver failure.
That's big news! And we thought you might like to get a first-glimpse
of the company as it sets out to acheive its business plan. We'll
be bringing you a full profile very soon, so stay tuned...
ABOUT HPLF
HepaLife is a development stage biotechnology company
focused on the research, development and eventual commercialization
of technologies and products to treat various forms of liver dysfunction
and disease.
|
HIGHLIGHTS
FROM THIS WEEK'S NEWS RELEASE FROM HEPALIFE |
|
Press Release
Source: HepaLife Technologies, Inc.
Monday July 21, 9:30 am ET
25 Million
Americans Afflicted With Liver Disease
VANCOUVER, British Columbia, July 21, 2003 (PRIMEZONE)
-- Presently, through a Cooperative Research and Development Agreement
(CRADA) with the USDA's Agricultural Research Service, the primary
tool linking government and industry researchers, HepaLife
Technologies, Inc. is collaborating towards optimizing the
hepatic functions of a patented cell line, whose hepatic characteristics
have been demonstrated to have potential application in the production
of an artificial liver device for use by human patients with liver
failure.
Liver Transplants
For people with severe liver failure, orthotopic liver transplantation
is the only effective treatment therapy and is now an estimated
$1.5 billion business. At present, there are upwards of 17,000
adults and children medically approved and waiting for liver transplants
in the U.S., which, at approximately $300,000 per transplant,
would increase the potential size of the liver transplant market
to over $5 billion if enough donor organs were available.
Unfortunately, there are just over 5,000 livers available for
transplant annually. Due to a severe shortage of organ donors,
the waiting time for potential liver recipients could be as long
as two to three years, with 20-30% of these patients not surviving
the wait period.
Liver Disease
and Hepatitis
According to the American Liver Foundation, 1 in every 11, or
approximately 25 million Americans are afflicted with liver disease.
During 2000 alone, 26,552 people died in the United States as
a consequence of cirrhosis and chronic liver disease (National
Vital Statistics Report, September 16, 2002).
In purely economic terms, liver-related problems cost society
over $10 billion per year.
Artificial
Liver Device
The need for an artificial liver device able to remove toxins
and improve immediate and long-term survival rates for patients
suffering from liver disease is more critical today than ever
before.
Limited treatment options, a low number of donor organs, the
high price of transplants and follow up costs, a growing base
of hepatitis, alcohol abuse, drug overdoses and other factors
that result in liver disease, all clearly indicate that a strong
need exists for an artificial liver device, now and into the foreseeable
future.
To read the entire press release and
the Safe Harbor, click
here
For a current quote on HPLF, click
here
To review the SEC filings for HepaLife,
click
here
|
A
BRIEF OVERVIEW OF HEPALIFE SHARES & FINANCIALS |
|
Recent Price: $1.84 (07-23-03)
Recent Volume: 62,500 (07-23-03)
Fiscal Year End: 12-31
|
Authorized Shares: 300,000,000
Shares Outstanding: 56,613,332
Transfer Agent: Holladay Stock
|
|
TO
CONTACT HPLF |
|
HepaLife Technologies, Inc.
Investor Relations
www.HepaLife.com
800.518.4879
Want
to feature YOUR company to over 1 MILLION investors?
Click
here to
learn more about our programs or email us directly at info@stockupticks.com
Stockupticks
Safe Harbor Statement: Statements contained in this document,
including those pertaining to estimates and related plans, potential
mergers and acquisitions, estimates, growth, establishing new markets,
expansion into new markets and related plans other than statements
of historical fact, are forward-looking statements subject to a
number of uncertainties that could cause actual results to differ
materially from statements made. StockUpTicks.com is a property
of Market Pathways Financial Relations Incorporated (MP).
MP provides no assurance as to the subject company's plans or ability
to effect any planned and/or proposed actions. MP has no first-hand
knowledge of management and therefore cannot comment on its capabilities,
intent, resources, nor experience and makes no attempt to do so.
Statistical information, dollar amounts, and market size data was
provided by the subject company and related sources believed by
MP to be reliable, but MP provides no assurance, and none is given,
as to the accuracy and completeness of this information.
Disclaimer:
StockUpTicks.com is a property of Market Pathways Financial Relations
Incorporated (MP). The information, opinions and analysis
contained herein are based on sources believed to be reliable
but no representation, expressed or implied, is made as to its
accuracy, completeness or correctness. Past performance
is no guarantee of future results. This report is a paid advertisement
and is for information purposes only and should not be used as
the basis for any investment decision. MP
has been compensated $15,000 by National Infosystems, Inc. for
preparation and distribution of this report and other advertising
services. This constitutes a conflict of interest as to
MP’s ability to remain objective in its communication regarding
the subject company. Write or call MP for detailed disclosure
as required by Rule 17b of the Securities Act of 1933/1934.
MP is not an investment advisor and this report is not investment
advice. This information is neither a solicitation to buy nor
an offer to sell securities but is a paid advertisement.
Information contained herein contains forward-looking statements
and is subject to significant risks and uncertainties, which will
affect the results. The opinions contained herein reflect
our current judgment and are subject to change without notice.
MP and/or its affiliates, associates and employees from time to
time may have either a long or short position in securities mentioned.
Information contained herein may not be reproduced in whole or
in part without the express written consent of Market Pathways
Financial Relations Incorporated.
|
|
